Related Experiment Videos
The response of plasma fibronectin to acute myocardial infarction in humans
R F Dyck1, R C Orchard, D L Senger
1Department of Medicine, University Hospital, Saskatoon, Saskatchewan.
Insights
Plasma fibronectin levels were lower in complicated acute myocardial infarction (AMI) cases. Intracoronary streptokinase use correlated with higher fibronectin, suggesting diagnostic and systemic response insights for AMI.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Background:
- Acute myocardial infarction (AMI) is a critical cardiovascular event.
- Plasma fibronectin, a hepatocyte-derived protein, plays a role in tissue repair and inflammation.
- Understanding biomarkers for AMI complications is crucial for patient management.
Purpose of the Study:
- To investigate plasma fibronectin levels in patients with complicated versus uncomplicated acute myocardial infarction.
- To explore the relationship between fibronectin levels and the use of intracoronary streptokinase.
- To assess the diagnostic potential of fibronectin in acute myocardial injury.
Main Methods:
- Prospective assessment of 166 Coronary Care Unit patients over six months.
- Measurement of plasma fibronectin levels using electroimmunoassay on admission and daily.
- Comparison of fibronectin levels between complicated and uncomplicated AMI groups.
Main Results:
- Significantly lower plasma fibronectin levels were observed 48 hours post-symptom onset in complicated AMI patients.
- Patients receiving intracoronary streptokinase exhibited consistently higher plasma fibronectin levels.
- Fibronectin levels differed between complicated and uncomplicated acute myocardial infarction cases.
Conclusions:
- Plasma fibronectin levels show potential as a diagnostic marker for acute myocardial infarction complications.
- Alterations in fibronectin levels may offer insights into the systemic response to myocardial injury.
- Fibronectin levels are influenced by thrombolytic therapy in AMI patients.
Abstract:
The purpose of this study was to investigate the plasma fibronectin response to complicated and uncomplicated acute myocardial infarction. All patients admitted to a Coronary Care Unit over a six-month period were prospectively assessed by measuring admission and daily plasma fibronectin levels using an electroimmunoassay. Of 166 patients admitted to the Unit, 66 were diagnosed as having an acute myocardial infarction. Plasma fibronectin levels were significantly lower 48 h after the onset of symptoms in 15 patients with a complicated acute myocardial infarction, compared to fibronectin levels in patients with an uncomplicated course; patients who had received intracoronary streptokinase had consistently higher plasma fibronectin levels than those seen in patients who did not receive this thrombolytic agent. This hepatocyte-derived plasma protein not only has diagnostic potential, but alterations in its levels may also provide insight into the systemic response to acute myocardial injury.